e-learning
resources
ERJ
2006
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Leigh R., Pizzichini M. M. M., Morris M. M., Maltais F., Hargreave F. E., Pizzichini E.
Source:
Eur Respir J 2006; 27: 964-971
Journal Issue:
May
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Leigh R., Pizzichini M. M. M., Morris M. M., Maltais F., Hargreave F. E., Pizzichini E.. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006; 27: 964-971
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline
Source: Annual Congress 2005 - Therapeutic options for COPD: present and future
Year: 2005
The role of nebulised budesonide in the treatment of exacerbations of COPD
Source: Eur Respir J 2007; 29: 660-667
Year: 2007
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?
Source: Eur Respir J 2003; 21: 260-266
Year: 2003
Inhaled corticosteroids and hospitalisation due to exacerbation of COPD
Source: Eur Respir J 2003; 22: 286-289
Year: 2003
Effects of inhaled corticosteroids on airway inflammations of different types in patients with chronic obstructive pulmonary disease or asthma in stable phase
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009
Low-dose inhaled and nasal corticosteroid use and the risk of cataracts
Source: Eur Respir J 2006; 27: 1168-1174
Year: 2006
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?
Source: Eur Respir J 2002; 19: 928-935
Year: 2002
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids
Source: Eur Respir J 2017; 49(1): 1600839; DOI: 10.1183/13993003.00839-2016
Year: 2017
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids
Source: Eur Respir J, 49 (6) 1700848; 10.1183/13993003.00848-2017
Year: 2017
Inhaled budesonide suppresses airway and systemic eosinophilic inflammation in COPD. No predictive value of a prednisolone test treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 290s
Year: 2005
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009
Where current pharmacological therapies fall short in COPD: symptom control is not enough
Source: Eur Respir Rev 2007; 16: 98-104
Year: 2007
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 514s
Year: 2001
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
Source: Eur Respir J 2007; 29: 906-913
Year: 2007
Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 515s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept